Scans reveal if new drug clears deadly heart protein
NCT ID NCT06073587
Summary
This study uses special heart scans to see if an investigational drug, eplontersen, can reduce the buildup of a harmful protein in the heart. It involves up to 150 people who already have a heart condition called ATTR amyloidosis and are part of a larger drug trial. The main goal is to compare scan images from the start of the study to those taken after about 2.5 years of treatment to measure any change in the amount of protein in the heart.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Hospital Universitario Puerta de Hierro
Majadahonda, 28222, Spain
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.